Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre

被引：15

作者：

Zoellner, Caroline ^{[1
,2
]}

Hofmann, Joerg ^{[3
]}

Lutz, Katrin ^{[1
,2
]}

Tacke, Frank ^{[1
,2
]}

Demir, Muenevver ^{[1
,2
]}

机构：

[1] Charite Univ Med Berlin, Dept Hepatol & Gastroenterol, Campus Virchow Klinikum CVK, Augustenburger Pl 1, D-13353 Berlin, Germany

[2] Campus Charite Mitte CCM,Augustenburger Pl 1, D-13353 Berlin, Germany

[3] Charite Univ Med Berlin, Inst Virol, Campus Charite Mitte, Berlin, Germany

来源：

LIVER INTERNATIONAL | 2022年 / 42卷 / 11期

关键词：

entry inhibitor; HDV therapy; real-life; VIRUS;

D O I：

10.1111/liv.15408

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection. We describe the first 48 weeks of bulevirtide therapy in eight patients (n = 7 male, n = 1 female; n = 3 compensated cirrhosis) treated at our centre. Median ALT values declined from 82 to 34 U/L after 48 weeks. Median HDV RNA dropped from 13 380 000 to 3135 copies/ml. One patient showed no significant response and was discontinued at week 16. Overall, we observed a favourable safety profile and a marked biochemical and virological response in the majority of our patients.

引用

页码：2403 / 2407

页数：5

共 10 条

[1] Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Karasahin, Omer
Kalkan, Irem Akdemir
Dal, Tuba
Toplu, Sibel Altunisik
Harputoglu, Murat
Mete, Ayse Ozlem
Komur, Suheyla
Sarigul, Figen
Yildiz, Yesim
Esmer, Fatih
Kandemir, Ozlem
Nazik, Selcuk
Inan, Dilara
Akgul, Fethiye
Kaya, Safak
Tunc, Nurettin
Balin, Safak Ozer
Bayindir, Yasar
Tasova, Yesim
Akar, Fesih
Oren, Meryem Merve
Ayhan, Merve
Demir, Yakup
Celen, Mustafa K.
HEPATITIS MONTHLY, 2021, 21 (02)
[2] Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital
Aikaterini Tsentemeidou
Elena Sotiriou
Efstratios Vakirlis
Nikolaos Sideris
Aimilios Lallas
Demeter Ioannides
Archives of Dermatological Research, 2022, 314 : 301 - 305
[3] Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital
Tsentemeidou, Aikaterini
Sotiriou, Elena
Vakirlis, Efstratios
Sideris, Nikolaos
Lallas, Aimilios
Ioannides, Demeter
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (03) : 301 - 305
[4] An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens
El Kassas, Mohamed
Alboraie, Mohamed
Omran, Dalia
Salaheldin, Mohamed
Wifi, Mohamed Naguib
ElBadry, Mohamed
El Tahan, Adel
Ezzat, Sameera
Moaz, Enass
Farid, Amir M.
Omar, Heba
Abouelkhair, Mahmoud
Afify, Shimaa
Elsaeed, Kadry
Shazly, Yehia
Doss, Wahid
Esmat, Gamal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (12) : 1265 - 1272
[5] Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt
Ahmed, Marwa M.
O. Shaarawy, Hagar
Anwar, Ismail
Sarhan, Mai D.
JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2021, 12
[6] Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register
Antonucci, Emilia
Migliaccio, Ludovica
Abbattista, Maria
Caronna, Antonella
De Marchi, Sergio
Di Giorgio, Angela
Di Giulio, Rosella
Lerede, Teresa
Garzia, Maria Grazia
Martinelli, Ida
Mastroiacovo, Daniela
Marzolo, Marco
Montevecchi, Elisa
Pastori, Daniele
Pignatelli, Pasquale
Poli, Daniela
Ria, Luigi
Santoliquido, Angelo
Testa, Sophie
Palareti, Gualtiero
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
[7] Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
Varga, Gergely
David Toth, Andras
Reka Szita, Virag
Csukly, Zoltan
Hardi, Apor
Gaal-Weisinger, Julia
Nagy, Zsolt
Altai, Elvira
Rencsik, Annamaria
Plander, Mark
Szendrei, Tamas
Korad, Krisztina
Radvanyi, Gaspar
Rottek, Janos
Deak, Beata
Szaleczky, Erika
Schneider, Tamas
Kohl, Zoltan
Kosztolanyi, Szabolcs
Alizadeh, Hussain
Lengyel, Zsuzsanna
Modok, Szabolcs
Borbenyi, Zita
Lovas, Szilvia
Varoczy, Laszlo
Illes, Arpad
Rajnics, Peter
Masszi, Tamas
Mikala, Gabor
PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
[8] Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort
Kallweit, Ulf
Jelcic, Ilijas
Braun, Nathalie
Fischer, Heike
Zoerner, Bjoern
Schreiner, Bettina
Sokolov, Arseny A.
Martin, Roland
Weller, Michael
Linnebank, Michael
CLINICAL NEUROPHARMACOLOGY, 2012, 35 (02) : 77 - 80
[9] Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
Maggi, Paolo
Ricci, Elena Delfina
Martinelli, Canio Vito
De Socio, Giuseppe Vittorio
Squillace, Nicola
Molteni, Chiara
Masiello, Addolorata
Orofino, Giancarlo
Menzaghi, Barbara
Bellagamba, Rita
Vichi, Francesca
Celesia, Benedetto Maurizio
Madeddu, Giordano
Pellicano, Giovanni Francesco
Carleo, Maria Aurora
Cascio, Antonio
Parisini, Andrea
Taramasso, Lucia
Valsecchi, Laura
Calza, Leonardo
Rusconi, Stefano
Sarchi, Eleonora
Martini, Salvatore
Bargiacchi, Olivia
Falasca, Katia
Cenderello, Giovanni
Ferrara, Sergio
Di Biagio, Antonio
Bonfanti, Paolo
VIRUSES-BASEL, 2023, 15 (07):
[10] Real life experience with nivolumab for the treatment of non-small cell lung carcinoma Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute
Schouten, Robert D.
Muller, Mirte
de Gooijer, Cornedine J.
Baas, Paul
van den Heuvel, Michel
LUNG CANCER, 2018, 126 : 210 - 216

← 1 →